| IV placebo | IV golimumab, 2 mg/kg | All patients |
---|---|---|---|
Number of patients | 239 | 241 | 480 |
Age (years), mean (SD) | 46.7 (12.5) | 45.7 (11.3) | 46.2 (11.9) |
Male, n (%) | 121 (50.6) | 128 (53.1) | 249 (51.9) |
White, n (%) | 237 (99.2) | 241 (100) | 478 (99.6) |
Body mass index (kg/m2), mean (SD) | 28.9 (6.2) | 28.9 (6.4) | 28.9 (6.3) |
Duration of PsA (years), mean (SD) | 5.3 (5.9) | 6.2 (6.0) | 5.8 (6.0) |
Swollen joint count (0–66), mean (SD) | 14.1 (8.2) | 14.0 (8.4) | 14.0 (8.3) |
Tender joint count (0–68), mean (SD) | 26.1 (14.4) | 25.1 (13.8) | 25.6 (14.1) |
Patient pain VAS (0–10), mean (SD) | 6.4 (2.1) | 6.3 (2.1) | 6.3 (2.1) |
Patient global disease activity VAS (0–10), mean (SD) | 6.3 (2.1) | 6.5 (1.9) | 6.4 (2.0) |
Physician global disease activity VAS (0–10), mean (SD) | 6.4 (1.6) | 6.2 (1.7) | 6.3 (1.6) |
≥ 3% BSA psoriasis skin involvement, n (%) | 198 (82.8) | 196 (81.3) | 394 (82.1) |
 PASI score (0–72), mean (SD)1 | 8.9 (9.0) | 11.0 (9.9) | 9.9 (9.5) |
PASDAS, mean (SD)2 | 6.7 (1.1) | 6.7 (1.1) | 6.7 (1.1) |
DAPsA, mean (SD)3 | 72.8 (32.1) | 71.8 (34.0) | 72.3 (33.0) |
CDAI score (0–76), mean (SD)2 | 34.4 (13.1) | 33.3 (12.5) | 33.8 (12.8) |
HAQ-DI (0–3), mean (SD | 1.3 (0.6) | 1.3 (0.6) | 1.3 (0.6) |
C-reactive protein (mg/dL), mean (SD) | 2.0 (2.1) | 1.9 (2.5) | 2.0 (2.3) |
Patients with dactylitis, n (%) | 124 (51.9) | 134 (55.6) | 258 (53.8) |
 Dactylitis score (1–60)4, mean (SD) | 9.9 (10.1) | 9.3 (9.4) | 9.6 (9.7) |
Patients with enthesitis, n (%) | 181 (75.7) | 185 (76.8) | 366 (76.3) |
 Leeds Enthesitis Index score (1–6)4, mean (SD) | 3.2 (1.6) | 3.0 (1.6) | 3.1 (1.6) |
Total PsA-modified SHS (0–528), mean (SD) | 34.5 (53.5) | 35.5 (55.2) | 35.0 (54.3) |
Baseline use of: | |||
 Methotrexate, n (%) | 173 (72.4) | 163 (67.6) | 336 (70.0) |
  Mean (SD) dose (mg/week) | 14.9 (4.8) | 14.8 (4.7) | 14.8 (4.7) |
 Oral corticosteroids, n (%) | 67 (28.0) | 66 (27.4) | 133 (27.7) |
  Mean (SD) dose (mg/day) | 7.6 (2.5) | 7.4 (2.6) | 7.5 (2.6) |